FDA approves eyelash-booster
FDA health officials have recently approved Latisse as an effective medication in promoting longer, thicker and darker eyelashes.
Latisee origins from a prescription eye drop, Lumigan, originally used to relieve eye pressure and treat glaucoma; eyelash growth was reported as one of its side effects.
Recent studies have reported that the drug can effectively promote eyelash growth, thickness, and darkness when applied to eyelash roots as eyeliner.
Eye redness is the only side effect reported following the use of the drug; this mild temporary complication, however, goes away when the drug is discontinued.
Lumigan's prescription information notes warn consumers about darkening of the eyelid skin and eye color (increased iris pigmentation), which are permanent but not noticeable in short-term use.
This adverse reaction is not reported following the use of Latisse as the new drug contains only 5 percent of a Lumigan drop and it is not directly applied to the eyes.
